https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18

 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

https://dinamiqs.com/  

8952 Schlieren, Wagistrasse 25

 info@dinamiqs.com

We are a science-driven contract development and manufacturing organization offering end-to-end viral vector manufacturing solutions. We offer customized services for companies and institutions developing innovative genetic medicines. As a science and technology-driven platform, we provide a comprehensive approach to viral vector manufacturing, from lab-scale development to scalable bioreactor implementation, process optimization, formulation, and stringent quality control.

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

http://www.insphero.com  

8952 Schlieren, Wagistrasse 27

 +41 44 515049-0
 info@insphero.com

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company currently counts all of the top ten global pharmaceutical and cosmetics companies as customers and is helping them to implement its patented microtissue technology in their development work-flow.

http://immunostherapeutics.com/  

8952 Schlieren, Wagistrasse 14

 info@immunostherapeutics.com

ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing the next generation of novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and costimulatory agonists for cancer therapy. The company is actively discussing and exploring new strategic collaborations with leading global pharmaceutical companies.

http://www.lmtbio.com  

8952 Schlieren, Grabenstrasse 3

 +41 44 733 85 85
 info@lmtbio.com

LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation bioconjugate vaccines using glycoengineering and protein glycosylation techniques previously developed by GlycoVaxyn and now owned by GSK. It was founded as a spin-off of GlycoVaxyn AG, which was acquired by GSK in February 2015 following a two-year collaboration. LimmaTech is developing vaccines exclusively for GSK and actively explores applications of glycoengineering and protein glycosylation technology in other fields.

https://kurosbio.com/  

8952 Schlieren, Wagistrasse 25

 +41 (0)44 733 4747

Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing.